CPC
TGTX icon

Cookson Peirce & Co’s TG Therapeutics TGTX Stock Holding History

Cookson Peirce & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,166
Closed -$1.27M – 349
2025
Q2 		$1.27M Buy
35,166
+2,424
+7% +$90.2K 0.06% 135
2025
Q1 		$1.29M Buy
32,742
+4,661
+17% +$157K 0.06% 113
2024
Q4 		$845K Buy
28,081
+10,718
+62% +$308K 0.04% 146
2024
Q3 		$406K Buy
+17,363
New +$379K 0.02% 206

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cookson Peirce & Co's TGTX Position: Q3 2025 in Review

Cookson Peirce & Co sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 35,166 shares — an estimated $1.27M sold.

Cookson Peirce & Co first reported a position in TGTX in Q3 2024 and held it in 4 quarters. The position peaked at $1.29M in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Cookson Peirce & Co reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cookson Peirce & Co sold 35,166 TG Therapeutics shares in Q3 2025, an estimated $1.27M.
  • Cookson Peirce & Co first reported a position in TG Therapeutics in Q3 2024 and held it in 4 quarters.
  • Cookson Peirce & Co's TG Therapeutics position peaked at $1.29M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Cookson Peirce & Co's 13F filing for Q3 2025, filed 6 Nov 2025.